Patents Assigned to Dynamix Pharmaceuticals LTD.
  • Sulfonamides for the modulation of PKM2
    Patent number: 8692001
    Abstract: The invention relates to sulfonamide compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: April 8, 2014
    Assignee: Dynamix Pharmaceuticals Ltd.
    Inventors: Oren M. Becker, Alina Shitrit, Nili Schutz, Efrat Ben-Zeev, Avihai Yacovan, Rachel Ozeri, Tzofit Kehat, Sima Mirilashvili, Alex Aizikovich, Daniel Sherman, Vered Behar, Osnat Kashtan
  • Compositions and Methods for Modulating a Kinase
    Publication number: 20120316148
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase signaling cascade.
    Type: Application
    Filed: June 7, 2012
    Publication date: December 13, 2012
    Applicant: Dynamix Pharmaceuticals LTD.
    Inventors: Oren M. Becker, Itai Bloch, Efrat Ben-Zeev, Alina Shitrit, Avihai Yacovan, Sharon Gazal, Vered Behar, Alexander Konson, Nili Schutz, Sima Mirilashvili, Gali Golan
  • Pyrazolines for the Modulation of PKM2
    Publication number: 20120302609
    Abstract: The invention relates to pyrazoline substituted compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.
    Type: Application
    Filed: May 23, 2012
    Publication date: November 29, 2012
    Applicant: Dynamix Pharmaceuticals LTD.
    Inventors: Oren M. Becker, Alina Shitrit, Nili Schutz, Efrat Ben-Zeev, Avihai Yacovan, Rachel Ozeri, Daniel Sherman, Vered Behar, Osnat Kashtan, Alexander Konson